Asist. Univ. Dr. Dan-Alexandru Niculescu

Dr. Dan Alexandru Niculescu este medic primar endocrinologie si are compententa in ecografia endocrina si este densitometrist clinic certificat  – The International Society for Clinical Densitometry.

• 2003–2011: Doctor în Medicină, Universitatea de Medicină și Farmacie Carol Davila, București
• 1996–2002: Medic, Universitatea de Medicină și Farmacie Carol Davila, București
• 1992–1996: Absolvent de Bacalaureat, Colegiul Național "Sfântul Sava", București

Proiecte de cercetare:

DIRECTOR DE PROIECT

• 2014 – 2017 Role of serum insulin-like growth factor I (IGF-I) and free fatty acids in insulin resistance, insulin secretion and glucose intolerance of acromegaly – grant UMF “Carol Davila”
  28332/04.11.2013, 5 000 EUR; publicații: Niculescu DA, Dusceac R, Caragheorgheopol A, Popescu N, Poiana C. Disposition Index in Active Acromegaly. Fron Endocrinol (Lausanne) 2019, 10: 637; doi: 10.3389/fendo.2019.00637 (factor de impact 3.634).
• 2007 Insulin resistance – the link between sleep apnea and high blood pressure in acromegaly - grant CNCSIS TD 428/2007, 15 000 EUR; publicații: teza de doctorat "Rolul GH/IGF-1 și al apneei de somn în producerea rezistenței la insulină și prognosticul diabetului zaharat acromegalic” – susținută 11.10.2011

MEMBRU ÎN ECHIPA DE CERCETARE

• 2015 – 2017 Correlations of bone mineral density with parathyroid function in end-stage renal disease – grant POSDRU/159/1.5/S/135760 CERO – PROFIL DE CARIERĂ: CERCETĂTOR ROMÂN, Contract 5584/5 din 02.03.2015, 5700 EUR; publicații: Dusceac R, Niculescu DA, Ismail G, Poiana C. Radius age-adjusted bone bineral density is correlated with parathyroid hormone serum levels in patients with end-stage renale disease. Acta Endo (Buc) 2015, 11(2): 175; doi: 10.4183/aeb.2015.175 (factor de impact 0.449).
• 2012 – 2015 MEDIGENE: Genetic and environmental factors of insulin resistance syndrome and its long-term complications in immigrant Mediterranean populations FP7 contract 279171, 2 996 907 EUR
• 2007 – 2009 Association case-control study between calpain 10 and insulin resistance in polycystic ovary syndrome – grant CNCSIS A 1333/2007, 30 000 EUR
• 2007 – 2010 Plasticity of human anterior pituitary cells against resistance to chemotherapy with dopamine agonists in lactotroph pituitary adenomas – grant PNCDI 2 – 41-014/2007

Premii 

• 2016 International Travel Grant la întâlnirea anuala AACE din Orlando pentru lucrarea Niculescu DA,Dusceac R, Galoiu S, Capatina C, Poiana C ”Evolution of liver function tests in newly diagnosed, overt hyperthyroidism treated with methimazole” - poster 1207
• 2010 International Travel Grant la întâlnirea anuală AACE din Boston pentru lucrarea Niculescu DA, Gheorghiu ML, Baciu I, Stefanescu AM, Badiu C, Poiana C, Radian S, Trifanescu R, Coculescu M ”Evaluation of an enzyme immunoasay for plasma and urinary metanephrines in the diagnosis of pheochromocytoma” - poster 106

Teza de doctorat:

• “Rolul GH/IGF-1 i al apneei de somn în producerea rezisten ș ței la insulină și
  prognosticul diabetului zaharat acromegalic” – susținută 11.10.2011
• Niculescu DA, Dusceac R, Caragheorgheopol A, Popescu N, Poiana C. Disposition Index in Active Acromegaly. Fron Endocrinol (Lausanne) 2019, 10: 637; doi: 10.3389/fendo.2019.00637 (factor de impact 3.634).
• Dusceac R, Niculescu DA, Dobre R, Dragne MC, Tacu C, Peride I, David C, Checherita I, Poiana C. Chronic hemodialysis is associated with lower trabecular bone score, independent of bone mineral density: a case-control study. Arch Osteoporos 2018 13(1): 125; doi: 10.1007/s11657-018-0541-6 (factor de impact 2.469).
• Niculescu DA, Capatina CAM, Dusceac R, Caragheorgheopol A, Ghemigian A, Poiana C. Seasonal variation of serum vitamin D levels in Romania. Arch Osteoporos 2017, 12(1): 113; doi: 10.1007/s11657-017-0407-3 (factor de impact 2.469).
• Niculescu DA, Baciu IF, Capatina C, Galoiu SA, Gheorghiu ML, Radian S, Trifanescu RA,
  Caragheorgheopol A, Coculescu M, Poiana C. Acromegaly treatment in Romania. How close are we to disease control? Endokrynol Pol 2017, 68(5): 519; doi: 10.5603/EP.a2017.0041 (factor de impact 1.521).
• Niculescu DA, Dusceac R, Galoiu SA, Capatina CA, Poiana C. Serial Changes of Liver Function
  Tests Before and During Methimazole Treatment in Thyrotoxic Patients. Endocr Pract 2016, 22(8): 974; doi: 10.4158/EP161222.OR (factor de impact 4.149).
• Niculescu DA, Ismail G, Poiana C. Plasma Free Metanephrine and Normetanephrine Levels Are
  Increased in Patients with Chronic Kidney Disease. Endocrine Practice 2014, 20(2): 139; doi:
  10.4158/EP13251.OR (factor de impact 4.149).
• Niculescu DA, Purice M, Coculescu M. Insulin-like growth factor-I correlates more closely than
  growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary 2013, 16(2): 168; doi: 10.1007/s11102-012-0396-6 (factor de impact 3.335).
• Coculescu M, Niculescu D, Lichiardopol R, Purice M. Insulin resistance and insulin secretion in nondiabetic acromegalic patients. Exp Clin Endocrinol Diabetes 2007, 115(5): 308; doi: 10.1055/s-2007- 961797 (factor de impact 1.927).
• Niculescu DA. Teza de doctorat? Cam așa… Smashwords 2017. ISBN: 9781370803163

Studii clinice internaționale

• A Phase III, double-blind, randomize, placebo-controlled, parallel-group multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency. NCT00294619 – subinvestigator.
• A phase III, open-label, uncontrolled, multicenter, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency. NCT00596037 –
  subinvestigator.
• A randomized, double-blind, parallel-group, multicenter, multinational study to assess the longterm effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial treatment period of 6 months with rimonabant 20 mg in overweight or obese patients. NCT00678483 – subinvestigator.
• A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone Deficiency (GHD). NCT00778518 – subinvestigator.
• Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the
  Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM
  23A760 in Acromegalic Patients. NCT00994214 – subinvestigator.
• Open Label Comparative Study Evaluating Efficacy and Safety of Oral Octreolin in Patients with
  Acromegaly Who are Currently Receiving Parenteral Somatostatin Analogs. NCT01412424 –
  subinvestigator.
• A Phase II, Randomized, Active Controlled, Open Label Studyof Safety and Efficacy of HM10560A a Long-Acting rhGH-HMC001Conjugate in Treatment of Subjects Suffering from Adult Growth Hormone